Kornimate/medical-research-clean huggingface dataset:
pathology, venous disease, and clinical correlations

Conditions: Varicose Veins; Pathology; Symptoms and Signs

Summary: chronic venous disease (cvd) has a high prevalence in the general population of the western world. varicose veins are the main signs of this disease that are characterized by important pathological vessel wall changes. there are also several symptoms that affect the quality of life of affected patients. the aim of this study is to correlate the main histopathological abnormalities with the type and the intensity of the symptoms.

chronic venous disease (cvd) of the lower limbs is a widespread chronic condition of the western world. there are several signs and symptoms that affect quality of life of patients with cvd. one of the main signs of this disease are varicose veins that are enlarged, swollen, and twisting superficial veins. vessel wall of varicose veins shows a significant histopathological phenotype, characterized by a distortion of structural architecture: endothelial damage, disorganization of muscle bundles and alteration of the composition of the extracellular matrix (ecm). symptoms may be different, according to disease state, progression and local inflammatory processes. to date, there is no study that correlate the type and the intensity of symptoms with histopathological phenotype. aim of this study is to correlate histopathological phenotype with clinical manifestations. a cohort of patients with varicose veins scheduled for open surgical treatment that will undergo to stab avulsion of varicose veins will be recruited. subsequently, venous tissue from stab avulsion will collected in order to evaluate the following biomarkers: vegf (vascular -endothelial growth factor), pgp 9.5 (protein gene product 9.5), fibronectin and matrix metalloproteinase- 9 (mmp-9). vegf has a key role as a regulator of angiogenesis; its expression is highly regulated by hypoxia, in this case induced by venous hypertension. in addition to being a marker of neoangiogenesis, it increases vascular permeability in inflammatory disorders. pgp 9.5 is a marker of the innervation of the vessel wall that plays an important role in the regulation of venous tone. fibronectin and mmp-9 are direct markers of ecm remodeling and impairment and they have also a role in chronic inflammation.

Eligibility criteria:
inclusion criteria: * patients with varicose veins scheduled for surgery exclusion criteria: * peripheral artery disease * malignancy

Keywords: pathology varicose veins chronic venous disease symptoms
revascularisation of autotransplanted teeth

Conditions: Endodontic Disease; Pulp Canal Obliteration

Summary: retrospective analysis of a study cohort that experienced autotransplantation of mature teeth with simultaneous root end resection note: the study was registered on clinicaltrials.gov after termination of study.


Eligibility criteria:
inclusion criteria: * male and female consenting and judicious young people and adults * written consent of the participant and, if applicable, of the legal guardian after education * planned tooth transplantation with advanced or completed root growth exclusion criteria: * contraindications for magnetic resonance imaging (mri): (pronounced metal restorations, running orthodontics with metal, fixed appliance in the target jaw) * current or past antiresorptive therapy with bisphosphonates * further anamnestic general or local risk situation, among others: anti-angiogenic therapy, history of local radiation therapy, severe coagulation disorder, unadjusted diabetes mellitus, malignant diseases * acute gingivitis or advanced periodontitis * participation in an ongoing drug trial (various drugs may distort the result, such as bisphosphonates, cortisone, chemotherapeutics, angiogenesis inhibitors) * heavy smokers (\> 10 per day) * acute or chronic infections (osteomyelitis) at the surgical site * metabolic diseases (diabetes, hyperparathyroidism, osteomalacia) * severe kidney dysfunction, severe liver disease * patients with high-dose corticosteroid therapy * prolonged corticosteroid or radiotherapy in the oral cavity * autoimmune diseases * pregnant or breastfeeding women

Keywords: autotransplantation, apicoectomy, revascularisation
clinical validation of cervical cancer screening methods

Conditions: Cervical Cancer; Cervical Dysplasia; Human Papilloma Virus

Summary: this single-institution cross-sectional non-inferiority validation study evaluates alternative techniques and tests for primary cervical cancer screening programs in russia, particularly: local cytology staining techniques, local hpv tests.

cervical cytology practices are different across the world. while the pap test became the cornerstone of the highly-effective cervical cancer screening in the countries that initially implemented population-based programs in the 60s and the 70s, alternative staining techniques were implemented in the soviet union. the tradition to apply other staining techniques than conventional pap test remained unchanged in the national screening program implemented in the 2010s in russia. as a new alternative option hpv testing showed effectiveness in screening women older than 30. the acceptable sensitivity and specificity of a screening test are crucial in population-based screening, that is why validation against "the gold standard" should be the first step in the process of program implementation. the objective of this study is to evaluate alternative techniques and tests for primary cervical cancer screening programs in russia, particularly: local cytology staining techniques, local hpv tests in the population of 25-65 yo women without prior history of malignancy referred to colposcopy enriched with a population sample of women from several primary healthcare facilities referred to a primary screening test.

Eligibility criteria:
inclusion criteria: age between 25 and 65 years old referral to colposcopy or to a primary screening test signed informed consent exclusion criteria: prior history of malignancy or cervical dysplasia prior history of cervical dysplasia
manual therapy/exercises vs. physiotherapy/back school vs. waiting list in patients with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: a randomized controlled trial for patients with chronic low back pain with two treatment arms and one waiting list control group. primary outcome is pain intensity on vas.


Eligibility criteria:
inclusion criteria: * pre-existing and specialist confirmed diagnosis of chronic low back pain for at least 3 months prior to inclusion * average pain intensity with at least 40 mm on the vas from 0 to 100 mm and pain on at least 5 of 7 weekdays in the last 3 months. exclusion criteria: * regular own exercise practice for the treatment of back pain (including yoga and other interventions) * invasive spinal procedures within the past 6 weeks or planned within the next 10 weeks * acute disc herniation (diagnosed within the last 3 months) * congenital deformities of the lumbar spine * rheumatoid arthritis * fibromyalgia * ankylosing spondylitis * severe comorbidities * pregnancy/lactation * current participation in another clinical trial
effect of liver cirrhosis on semen parameters and reproductive hormones

Conditions: Male Infertility

Summary: normal testicular hormonal and spermatogenic function depends not only on the testis itself, but also on the integrity of the hypothalamus and anterior pituitary. systemic diseases has been shown to influence male gonadal function in variety of ways, leading to reduced libido, erectile impotence, infertility, osteoporosis, and decreased physical stamina and muscle mass. the effect of systemic diseases may occur directly at the testicular level: reduced leydig cell function will lead to androgen deficiency, while diseases affecting spermatogenesis may lead to infertility. alternatively, acute and chronic illness may interfere with the hypothalamic-pituitary axis and lead to reduced testicular function.

liver is thoroughly involved in proteins, cytokines and interleukins synthesis and destruction. therefore, abnormal function of endocrine organs is expected in patients with liver cirrhosis. hypogonadism is a frequent clinical feature in patients with liver cirrhosis. these patients have gynecomastia, decreased libido, signs of feminization, testicular atrophy and low testosterone level, as well as reduced spermatogenesis. these features are more severe in patients with higher child pugh score. several hormonal abnormalities are responsible for these clinical alterations. estrogen/androgen ratio has been increased in cirrhosis while there is reduction in serum testosterone and dehydroepiandrosterone level. hyperprolactinemia is present in patients with cirrhosis and may involve in hypogonadism by an inhibitory effect on gonadotropins.

Eligibility criteria:
inclusion criteria: * male patient with liver cirrhosis of any etiology and severity. exclusion criteria: 1. systemic conditions like:chronic renal failure, diabetes mellitus, thyrotoxicosis, hypothyroidism, cushing's disease and cancer. 2. local conditions like :varicocele, urogenital infections, history of cryptorchidism, functional and obstructive azoospermia.
evaluating the effectiveness of the gill ehealth intervention to improve physical health and lifestyle behaviours in patients with severe mental illness

Conditions: Severe Mental Disorder; Metabolic Syndrome; Lifestyle; Somatic Screening; eHealth

Summary: the aim of this study is to evaluate the effectiveness of the nurse-led gill (gezondheid in lichaam en leefstijl) ehealth intervention in patients with serious mental illness (smi), compared to usual care. expected is that the gill ehealth intervention will be more effective than usual care in improving physical health and lifestyle behaviors. to evaluate this, we will perform a cluster randomized controlled trial with an embedded process evaluation of the implementation of the gill intervention. 258 adult patients with serious mental illness and a body mass index of 27 or higher (overweight/obesity) will be included. the gill ehealth intervention consists of two complementary modules for (a) somatic screening and (b) lifestyle promotion, resulting in a personalized somatic treatment and lifestyle plan. trained mental health nurses and clinical nurse specialists will implement the intervention within the multidisciplinary treatment context, and will guide and support the patients in the promotion of their somatic health, including cardiometabolic risk management. the intervention will be compared to usual care, which includes treatment according to national guidelines. the outcome measures will be metabolic syndrome severity (primary), fitness, physical activity, lifestyle behaviors, quality of life, recovery, psychosocial functioning, health related self-efficacy and health care utilization after 1 year. the process evaluation focuses on the feasibility of the ehealth intervention, its acceptability for patients and health care providers (mainly mental health nurses and clinical nurse specialists), and barriers/facilitators to implementation.


Eligibility criteria:
inclusion criteria: * meet the criteria of severe mental illness * aged from 18 to 65 years * body mass index (bmi) ≥ 27 * access and ability to use internet * able and willing to sign informed consent exclusion criteria: * contra-indications (to be assessed by the treating physician/psychiatrist) for participation due to acute psychiatric crisis or severe somatic diseases * subjects with a cognitive impairment sufficient to interfere with their ability to provide informed consent, complete study questionnaires, or participate in the intervention * pregnant or breastfeeding women at the time of inclusion * subject not able to communicate in the dutch language
auditory prediction and error evaluation in the speech of individuals who stutter

Conditions: Healthy Subjects; Stuttering, Developmental

Summary: stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. this study will provide a strong foundation for developing neural and behavioral interventions for stuttering. participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. some participants may also receive brain stimulation while reading and speaking.


Eligibility criteria:
inclusion criteria: * being a monolingual, native speaker of american english * absence of developmental, psychological, neurological, or communication disorders (other than developmental stuttering) as confirmed by a certified research slp * normal (age-appropriate) binaural pure-tone hearing threshold (0.5-4k hz; ≤25 db hl for younger than 70 years, and ≤35 db hl for older than 70 years) * not taking any medications that affect the central nervous system * absence of safety contra-indication for tdcs, tms and mri (for adults) * scoring at the 20th percentile or higher on standardized speech-language tests (for children) exclusion criteria: -

Keywords: stuttering
safety, efficacy, and pharmacokinetics of csl889 in adults and adolescents with sickle cell disease during vaso-occlusive crisis

Conditions: Sickle Cell Disease Vaso-occlusive Crisis

Summary: this study consists of two parts: phase 2 (part a) and phase 3 (part b). it is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (pk) of csl889 (human hemopexin) when given intravenously (iv) to adults and adolescents with sickle cell disease (scd) experiencing vaso-occlusive crises (voc). the main objectives of the study are to assess how csl889 affects the time it takes for voc to resolve in participants with scd, and to evaluate the safety and tolerability of csl889 in study participants.


Eligibility criteria:
inclusion criteria: •at the time of informed consent: \>= 18 years of age (adults); or \>= 12 to less than (\<) 18 years of age (adolescents, where approved and when enrollment for adolescents has been opened by the sponsor, with the endorsement of the independent data monitoring committee \[idmc\]). * diagnosed with scd (any genotype). * presented at the study site with a new acute voc necessitating treatment with parenteral opioids. exclusion criteria: * voc pain onset greater than or equal to (\>=) 72 hours before administration of first parenteral opioid (part a; may be adjusted for part b based on prespecified analysis). * must not have a history of greater than (\>) 5 vocs requiring hospital admission in the past 6 months; or signs and / or symptoms of acs; or new neurological symptoms suggestive of acute stroke or transient ischemic attack; or any stage (acute kidney injury) aki; or been discharged from inpatient hospital admission for voc or other vaso-occlusive event within 14 days before the current presentation. * serum hemoglobin \ = 2000 ng/ml, receiving an approved medication for scd that has not been on a stable, well-tolerated regimen, currently taking methadone or buprenorphine.

Keywords: sickle cell disease acute kidney injury pharmacokinetics acute chest syndrome vaso-occlusive crisis hemopexin
thermocool smarttouch®sf catheters with ablation index study

Conditions: Paroxysmal Atrial Fibrillation

Summary: a single-center, real word study of consecutive subjects who undergo radiofrequency ablation for paroxysmal af using thermocool smarttouch®sf (stsf) catheter guiding by ablation index (ai). prospectively or retrospectively record 150 eligible subjects since 1st jan 2019 to evaluate effectiveness and safety of stsf with ai.

the purpose of this study is to measure the long term effectiveness，clinical benefit, and safety outcomes of catheter ablation with stsf and ai for paroxysmal atrial fibrillation (paf) subjects up to 12-month follow-up. subject:up to 150 paf subjects will be included in the study data, representing all consecutive subjects having catheter ablation with ai guiding stsf and for the treatment of paf at the site. primary endpoint: the primary endpoint is freedom from documented atrial fibrillation (af), atrial tachycardia (at), or atrial flutter (afl) (≥30 seconds) within 91-365 days post index procedure. secondary endpoint : acute success at 0.5hour cpvi (i.e. entrance block achieved in all veins, verified via an isoproterenol intravenous challenge) * numbers of reconnected pulmonary veins (pv), with number and location of any gaps * procedural efficiency measures（e.g. mapping time, ablation time, total procedure time, and fluid volume delivered via catheter. * ai values * inter-tag distances * adverse events (complications related to device or procedure) * re-hospitalization due to arrhythmia recurrence or procedure-related reasons up to 1 year clinical study sites: shanghai general hospital study duration: 18-month enrollment period, with follow-up at 3, 6 and 12 months after ablation, with a blanking period defined as the period within 90 days after the ablation.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. patient has paf eligible for ai-guided catheter ablation with an stsf catheter per standard of care assessment 3. able and willing to comply with all pre-, post- and follow-up testing and requirements 4. able to sign ec-approved informed consent form exclusion criteria: 1. af is secondary to electrolyte imbalance, thyroid disease, or a reversible or non-cardiac cause 2. patient has af episodes lasting longer than 7 days 3. history of heart surgery, or any previous ablation for af 4. myocardial infarction (mi), coronary artery bypass grafting (cabg) or percutaneous coronary intervention (pci) within preceding 3 months 5. documented left atrial thrombus on imaging 6. new york heart association (nyha) class iii or iv heart failure 7. hypertrophic obstructive cardiomyopathy 8. presence of implantable cardioverter defibrillator (icd) 9. contraindication to isoproterenol 10. any other disease or malfunction that would preclude treatment with ablation in the opinion of the investigator 11. women who are pregnant and/or breast feeding 12. enrollment in an investigational study evaluating another device, biologic, or drug
pinpointe footlaser for the treatment of onychomycosis

Conditions: Infected Toenails; Onychomycosis

Summary: to evaluate the safety and efficacy of the patholase footlaser treatment of infected toenails.

the study is a multi-center controlled study evaluating laser treatments of infected great toes in a randomized blinded study of approximately 125 subjects. right and left great toes are randomized to treatment or no treatment. samples from infected areas are sampled and evaluated for presence of fungus with koh, pcr and culture tests. nail bed clearing and nail plate growth are measured from high resolution photographs by a blinded evaluator. subjects will be evaluated at baseline and at 8, 16, 24 and 48 weeks for safety and effectiveness of study treatment.

Eligibility criteria:
inclusion criteria: * volunteers of either sex, * 18-80 years of age, * both great toes with clinical signs of infection. * positive koh or culture test exclusion criteria: * existing or history of cancer/skin malignancy, * use of oral antifungal agents in past 6 months, * use of topical antifungal agents in past 1 month, * loss of protective sensation in either foot, * infection involving lunula of either great toe, * longitudinal streaks/spikes of either great toenail, * distal nail thickness \> 2 mm of either great toe, * prior surgical treatment of either great toe in past 12 months, * participation in another medical device/pharmaceutical study, * condition that investigator determines makes it unsafe for subject to participate, * pregnancy, breastfeeding or plans to become pregnant.

Keywords: toenail fungus pinpointe footlaser onychomycosis fungal nails
prf pulpotomy using different bioceramic materials in permanent molars

Conditions: Irreversible Pulpitis

Summary: this study aimed to compare the clinical and radiographic outcomes of full pulpotmy after application of biodentine, or mta, or portland cement above prf membrane in permanent molars with irreversible pulpitis


Eligibility criteria:
inclusion criteria: * spontaneous, lingering pain exacerbated by hot and cold , and/or radiating pain * responded to cold and electric pulp testing exclusion criteria: * pain on palpation, percussion, * mobility or swelling * peridontall widening * teeth with marginal periodontitis or crestal bone loss * resorption * calcified canals

Keywords: prf vital pulp therapy pulpotomy bioceramics
adjuvant serplulimab and trastuzuma and chemotherapy in her-2+ gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to find out whether treatment with serplulimab combined with trastuzumab and chemotherapy will improve the survival of gastric cancer patients with stage ii-iii after surgery.


Eligibility criteria:
inclusion criteria: 1. lower age limit of research subjects 20 years old and upper age limit of 80 years old. 2. be proven to be primary adenocarcinoma of gastric cancer and staged ii-iii by pathological evidences 3. r0 gastrectomy with d2 lymphadenectomy 4. her2+ diagnosed by immunohistochemistry or fish 5. ecog (ecog score standard) performance status of 0 or 1 and expected to survive more than 6 months 6. no contraindications, including normal peripheral blood routine, liver and kidney function and electrocardiogram （wbc≥3.5 x 109 /l, neu≥1.2 x 109 /l,plt≥90 x 109 /l and hgb≥80g/l). exclusion criteria: 1. patients with stage i and iv. 2. unavailable for r0 resection and d2 lymph node dissection. 3. multiple primary tumors 4. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases. 5. history of chemotherapy, radiotherapy, immunotherapy or target therapy.

Keywords: gastric cancer adjuvant treatment trastuzuma serplulimab
feasibility study of an intervention therapeutic education for patients treated with androgen deprivation

Conditions: Prostate Cancer

Summary: the purpose of the study is to build and assess the feasibility of a therapeutic education program, constructed in collaboration with the urologists of the university hospital of saint etienne. the aim of this therapeutic education program is to delay the onset or to reduce the amplitude of the development of insulin resistance and side effects of androgen deprivation therapy in patients treated with androgen deprivation in the context of an evolutive prostate cancer.


Eligibility criteria:
inclusion criteria: * patients supported in consultation urology at the university hospital north saint etienne. * aged over 18 years * having an evolutive prostate cancer * patient treated with lhrh agonist for at least 6 months - affiliated with the national health insurance system * and having completed the worksheet informed consent to participate in the program. exclusion criteria: * refusal of participation, protected or under guardianship patients. * patients unable to understand the study or unable to follow the educational sessions. * patient (s) with documented cognitive or psychiatric history. * geographical remotness (more than 100 kms.)

Keywords: therapeutic patient education insulinoresistance empowerment prostate cancer oral endocrine therapy side effects